New Biologic Telitacicept Cuts Kidney Protein Loss by 59% in Phase III IgA Nephropathy Trial
Telitacicept slashed urinary protein by 59% in 39 weeks, signaling a major advance for a kidney disease affecting millions worldwide.
Summary
IgA nephropathy is a progressive kidney disease where abnormal immune proteins accumulate in kidney tissue, gradually destroying function and often leading to dialysis. A new biologic drug called telitacicept, which blocks two immune signaling proteins called BAFF and APRIL, reduced a key marker of kidney damage — urinary protein — by nearly 59% over 39 weeks in a phase III clinical trial, versus just 9% in the placebo group. Published in the New England Journal of Medicine, the results suggest telitacicept could become a powerful new option for patients with this condition. The drug, already approved in China for lupus, appeared safe with few serious side effects beyond injection site reactions and modest reductions in other immune proteins.
Detailed Summary
IgA nephropathy is the world's most common primary glomerulonephritis — a kidney disease where immunoglobulin A proteins accumulate in kidney filters, progressively impairing function. It disproportionately affects young people and is a leading cause of kidney failure, yet targeted treatments have only emerged in the last few years. A new phase III trial adds significant momentum to this rapidly evolving treatment landscape.
The trial tested telitacicept, a fusion protein biologic that simultaneously inhibits two cytokines — BAFF and APRIL — both implicated in driving IgA nephropathy's underlying immune dysfunction. After 39 weeks, patients receiving telitacicept showed a 58.9% reduction in urinary protein-to-creatinine ratio, a critical surrogate marker for kidney damage, compared to just 8.8% in the placebo group. Results were published in the New England Journal of Medicine by researchers at Peking University First Hospital.
The drug's safety profile was reassuring. The only notable adverse effects were injection site reactions and mild reductions in other immunoglobulin levels, suggesting the drug is well tolerated. Telitacicept is already approved in China for lupus, giving it an established safety record in humans with immune-mediated diseases.
This trial represents an interim analysis at 39 weeks; the full study runs to 104 weeks, with the annualized rate of eGFR decline — a direct measure of kidney filtration capacity — as the final primary endpoint. Full results will determine whether the protein reduction translates into preserved kidney function over time.
Telitacicept enters a crowded but fast-moving field. Five other drugs now carry IgA nephropathy indications, including the closely related atacicept, which targets the same pathways and is pending accelerated U.S. approval. Competition is intensifying, which may accelerate access and drive refinement of treatment protocols for patients with this serious condition.
Key Findings
- Telitacicept reduced urinary protein-to-creatinine ratio by 58.9% vs 8.6% placebo over 39 weeks
- Drug targets both BAFF and APRIL cytokines, dual blockade may outperform single-target approaches
- Safety profile was favorable; main side effects were injection site reactions and minor immunoglobulin changes
- Full 104-week trial will measure eGFR decline as definitive kidney function endpoint
- IgA nephropathy treatment options have expanded rapidly since 2024 with multiple new drug approvals
Methodology
This is a news report summarizing a phase III randomized controlled trial published in the New England Journal of Medicine, a top-tier peer-reviewed journal. The 39-week data represent a prespecified interim analysis; final primary outcomes at 104 weeks are pending. Source credibility is high given the journal and institutional authors.
Study Limitations
The 39-week data are interim only; long-term kidney function outcomes (eGFR) are not yet available. The trial was conducted primarily in China, which may limit generalizability to Western populations. Comparative efficacy against other approved agents like sibeprenlimab or atacicept has not been directly tested.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.